# A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)

Source: https://onco.cc/trials/nct07108270/  
OnCo record `nct07108270` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Dostarlimab and Carboplatin in endometrial cancer, run by GlaxoSmithKline, now recruiting.

## Summary

A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC) is a phase 2 interventional study registered as NCT07108270 by GlaxoSmithKline, with 30 participants planned, started 2025-11-27 and due to reach its primary completion in 2030-03-31. Interventions recorded: Dostarlimab, Carboplatin and Paclitaxel.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07108270
- Phase: 2
- Setting: A Phase 2, Multicenter, Open-label, Single Arm Study of Dostarlimab Plus Carboplatin-paclitaxel Followed by Dostarlimab Monotherapy in Participants With dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer in China (China RUBY)
- Sponsor: GlaxoSmithKline
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT07108270: https://clinicaltrials.gov/study/NCT07108270

## Connected records

- cancers: [Endometrial cancer](https://onco.cc/cancers/endometrial/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Dostarlimab](https://onco.cc/drugs/dostarlimab/)
- companies: [GSK](https://onco.cc/companies/gsk/)

---
JSON: https://onco.cc/api/v1/entities/nct07108270.json